Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29128621 | 0.87 | KMT2A (0.57) | KMT2APOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL26789473 | 0.84 | POLB (0.59) | KMT2APOLBALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL12630078 | 0.80 | POLB (0.52) | KMT2APOLBALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL30516912 | 0.79 | POLB (0.51) | KMT2APOLBLMNASMN1; SMN2HTT | |
| SCHEMBL49946 | 0.78 | KMT2A (0.57) | KMT2APOLBALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3268236 | 0.78 | KMT2A (0.57) | KMT2APOLBALDH1A1SMN1; SMN2HSP90AA1 | |
| SCHEMBL9523223 | 0.77 | KMT2A (0.55) | KMT2APOLBALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1858809 | 0.76 | POLB (0.51) | KMT2APOLBLMNAL3MBTL1HSP90AA1 | |
| SCHEMBL1863466 | 0.75 | POLB (0.48) | KMT2APOLBLMNAHSP90AA1HSP90AB1 | |
| SCHEMBL2632922 | 0.75 | KMT2A (0.62) | KMT2APOLBALDH1A1SMN1; SMN2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157742-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ALLCRON PHARMA INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2023-12-14 | — | — | US | disclosed |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ALLCRON PHARMA INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ALLCRON PHARMA INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ALLCRON PHARMA INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3768682-B1 | 2-({2H,3H-[1,4]DIOXINO[2,3-G]QUINOLIN-7-YL}SULFANYL)ACETAMIDE DERIVATIVES AS BCR-ABL KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ALLCRON PHARMA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3768682-B1 | 2-({2H,3H-[1,4]DIOXINO[2,3-G]QUINOLIN-7-YL}SULFANYL)ACETAMIDE DERIVATIVES AS BCR-ABL KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ALLCRON PHARMA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20210040104-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040104-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3768682-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | Allcron Pharma Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019182944-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019182944-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040104-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ABL1, MCL1, ABL2 | KMT2A 370/4885POLB 3176/4885ALDH1A1 3210/4885 |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ABL1, MCL1, ABL2 | KMT2A 370/4885POLB 3176/4885ALDH1A1 3210/4885 |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ABL1, MCL1, ABL2 | KMT2A 358/4885POLB 2592/4885ALDH1A1 2686/4885 |
| US-12157742-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ABL1, MCL1, ABL2 | KMT2A 358/4885POLB 2592/4885ALDH1A1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.